Abstract
Many trypanosomatid protozoa, such as those belonging to the Trypanosoma and Leishmania genera cause serious diseases to man. Such parasites present an unusual feature, a mitochondrial DNA arranged in catenated circles, known as kinetoplast DNA (kDNA). The replication of kDNA network is a complex process, which involves many proteins. Some of them are classified as topoisomerases and play essential biological roles, not only on kDNA synthesis, but also in the dynamics of the network topology, constituting the main target for drugs in kinetoplast. DNA binding drugs are also reported as chemotherapeutic agents against trypanosomatid infections. This review summarizes what is known about kinetoplast as a potential chemotherapeutic target for trypanosomatid protozoa.
Keywords: Chemotherapy, DNA binding drugs, kinetoplast, topoisomerases, trypanosomatids
Current Pharmaceutical Design
Title: Kinetoplast as a Potential Chemotherapeutic Target of Trypanosomatids
Volume: 14 Issue: 9
Author(s): Maria Cristina Machado Motta
Affiliation:
Keywords: Chemotherapy, DNA binding drugs, kinetoplast, topoisomerases, trypanosomatids
Abstract: Many trypanosomatid protozoa, such as those belonging to the Trypanosoma and Leishmania genera cause serious diseases to man. Such parasites present an unusual feature, a mitochondrial DNA arranged in catenated circles, known as kinetoplast DNA (kDNA). The replication of kDNA network is a complex process, which involves many proteins. Some of them are classified as topoisomerases and play essential biological roles, not only on kDNA synthesis, but also in the dynamics of the network topology, constituting the main target for drugs in kinetoplast. DNA binding drugs are also reported as chemotherapeutic agents against trypanosomatid infections. This review summarizes what is known about kinetoplast as a potential chemotherapeutic target for trypanosomatid protozoa.
Export Options
About this article
Cite this article as:
Machado Motta Cristina Maria, Kinetoplast as a Potential Chemotherapeutic Target of Trypanosomatids, Current Pharmaceutical Design 2008; 14 (9) . https://dx.doi.org/10.2174/138161208784041051
DOI https://dx.doi.org/10.2174/138161208784041051 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Challenges and Opportunities for Cancer Vaccines in the Current NSCLC Clinical Scenario
Current Topics in Medicinal Chemistry Organoselenium Compounds as Potential Therapeutic and Chemopreventive Agents: A Review
Current Medicinal Chemistry Polysaccharide-K (PSK) in Cancer - Old Story, New Possibilities?
Current Medicinal Chemistry Cationic Liposome Mediated Delivery of FUS1 and hIL-12 Coexpression Plasmid Demonstrates Enhanced Activity against Human Lung Cancer
Current Cancer Drug Targets Molecules of Parasites as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry Oncogenic LncRNA CASC9 in Cancer Progression
Current Pharmaceutical Design Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Corrosion of Materials in Polluted Environment and Effect on World Economy
Recent Patents on Corrosion Science Editorial (Thematic Issue: Treatment of Cancer in the Elderly)
Anti-Cancer Agents in Medicinal Chemistry 1,3,4-Oxadiazole Derivatives as Potential Biological Agents
Mini-Reviews in Medicinal Chemistry Molecular Dynamics and Structural Studies of the Ets Domain-DNA Complexes
Current Bioinformatics Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth
Current Neurovascular Research Regulatory Role of the α7nAChR in Cancer
Current Drug Targets Is There an Increased Risk of Lymphoma and Malignancies Under Anti- TNF Therapy in IBD?
Current Drug Targets Hybrid Benzoxazole-Coumarin Compounds Induce Death Receptor-Mediated Switchable Apoptotic and Necroptotic Cell Death on HN-5 Head and Neck Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Advancements in Adjuvanticity of Bioactive Inorganic and Organic Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Integrins in Drug Targeting-RGD Templates in Toxins
Current Pharmaceutical Design A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic: Vasoactive Intestinal Peptide (VIP): Historic Perspective and Future Potential]
Endocrine, Metabolic & Immune Disorders - Drug Targets